



For Immediate Release

Symic Bio Appoints Scott W. Morrison to Board of Directors

SAN FRANCISCO, Jan. 30, 2017 – Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, today announced the appointment of Scott W. Morrison to its Board of Directors. Mr. Morrison was U.S. Life Sciences Leader at Ernst & Young LLP until his retirement in December 2015.

“For over 35 years, Scott has contributed in a variety of roles to realizing the promise of biotechnology,” said Ken Horne, Chief Executive Officer of Symic Bio. “We are proud that Scott will be able to share his enthusiasm, energy, vision and unusual breadth of experience with Symic Bio as we advance and expand our platform of therapeutics at the frontier of the industry - advancing applications in the area of matrix biology.”

Mr. Morrison has a long history of contributions to nonprofit and industry organizations and has previously served on the boards of the Life Sciences Foundation, the Bay Area Biosciences Association, the Emerging Companies Section of the Biotechnology Innovation Organization (BIO) and the Biotechnology Institute. In addition, Mr. Morrison currently serves on the boards of Audentes Therapeutics, Corvus Pharmaceuticals and Global Blood Therapeutics.

About Symic Bio

Symic Bio is a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

For additional information please visit the company’s website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contacts

Gitanjali Jain Ogawa
The Trout Group
(646) 378-2949
gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(646) 942-5588

david.schull@russopartnersllc.com

rich.allan@russopartnersllc.com